Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 369 | 57 | 309 |
| Samples | 194 | 36 | 156 |
| Peptides | 140 | 28 | 113 |
Function
SACM1L · SAC1 like phosphatidylinositide phosphatase
This gene encodes an integral membrane protein, which is localized to the endoplasmic reticulum, and functions as a phosphoinositide phosphatase that hydrolyzes phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, and phosphatidylinositol 3,5-bisphosphate. Deletion of this gene in mouse results in preimplantation lethality. Other studies suggest that this gene is also involved in the organization of golgi membranes and mitotic spindles. Alternatively spliced transcript variants have been found for this gene. A C-terminally extended isoform is also predicted to be produced by the use of an alternative in-frame, downstream translation termination codon via a stop codon readthrough mechanism.[provided by RefSeq, Dec 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 140 amino-acid changes on canonical ENST00000389061 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SACM1L · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SACM1L – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 9/612 1% |
| Colorectal Carcinoma | 7/143 5% | 25/3239 1% |
| Gastric Carcinoma | 3/74 4% | 12/1809 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Melanoma | 4/210 2% | 11/1899 1% |
| Glioma | 5/52 10% | 10/2127 0% |
| Hepatocellular Carcinoma | 0/46 0% | 15/2210 1% |
| Ovarian Carcinoma | 3/109 3% | 4/998 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 4/1390 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
| Esophageal Carcinoma | 1/23 4% | 2/769 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Breast Carcinoma | 0/144 0% | 4/3264 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 2/2640 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
Mutation Distribution
Where SACM1L is mutated · all tissues, split by cell line vs tissue
How many mutations in SACM1L were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 369 mutations in SACM1L
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|